Vivimed Labs Limited
NSE: VIVIMEDLAB · Pharmaceuticals · sector
₹5.97NSE close 2026-10-26
Key numbers
Market cap₹50 cr
Price₹5.97
52w high / low₹29 / ₹5
P/E–Sector median 27.9x
P/B–Sector median 2.9x
Book value₹-25.3
Dividend yield–Sector median 0.48%
ROE–Sector median 11.7%
ROCE-91.6%Sector median 12.3%
OPM-216.2%Sector median 14.0%
Debt / equity–Sector median 0.16x
EV/EBITDA–Sector median 18.6x
Interest cover-40.9x
Current ratio0.37x
Sales growth 3y-27.9%Sector median +9.6%
Profit growth 3y–Sector median +13.3%
PEG–
Last 12 months to Mar 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹1 cr vs borrowings ₹397 cr (FY26): borrowings are higher by ₹396 cr.
- Operating profit covered interest -40.9x in the last 12 months.
- 15.18% of the promoters' shares are pledged (1.1% of all shares).
- Promoter holding fell by 13.37 percentage points in a year, to 7.57% (2026-03-31).
- Operating cash flow was below net profit in 1 of the last 5 years (FY22).
- Net loss in 8 of the last 8 quarters.
- Revenue was higher than a year earlier in 0 of the last 4 quarters.
- Debtor days went from 203 (FY24) to 236 (FY26).
- No dividend in the last 5 financial years.
- Price ₹5.97 on 2026-10-26: -79.7% from the 52-week high, +25.7% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹22.81 · low ₹5.02
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 29 | 25 | 37 | 26 | 21 | 21 | 16 | 12 |
| EBITDA | -4 | -1 | 1 | -2 | -0 | -1 | -11 | -139 |
| OPM % | -13.4% | -2.6% | 2.9% | -7.8% | -1.3% | -4.6% | -68.3% | -1,159.9% |
| Other income | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 6 |
| Net profit | -8 | -5 | -6 | -5 | -5 | -7 | -17 | -146 |
| EPS (₹) | -0.99 | -0.60 | -0.72 | -0.67 | -0.66 | -0.88 | -0.88 | -17.74 |
| Revenue YoY | -27.2% | -16.8% | -56.2% | -53.1% | ||||
| Profit YoY | – | – | – | – |
Consolidated figures where filed. Latest quarter Mar 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 237 | 187 | 149 | 116 | 70 | 70 |
| EBITDA | -8 | -187 | -33 | -13 | -151 | -151 |
| Net profit | -68 | -328 | -45 | -32 | -175 | -175 |
| EPS (₹) | -8.16 | -39.62 | -5.48 | -3.85 | -21.15 | -20.16 |
| Revenue growth | -21.2% | -20.3% | -22.0% | -39.8% | -39.8% | |
| Profit growth | – | – | – | – | – | |
| Dividend / share (₹) | – | – | – | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | -27.9% | -39.5% | -39.8% |
| Net profit | – | – | – |
| EPS | – | – | – |
| Share price | – | – (2y) | – |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 39 | -5 | -35 | -211 |
| Borrowings | – | 379 | 377 | 847 | 397 |
| Cash & equivalents | – | 4 | 2 | 1 | 1 |
| Total assets | – | 988 | 951 | 921 | 753 |
| Fixed assets | – | 278 | 263 | 254 | 237 |
| Capital work in progress | – | 21 | 21 | 17 | 18 |
| Investments | – | 0 | 0 | 168 | 181 |
| Receivables | – | 77 | 83 | 74 | 45 |
| Inventory | – | 80 | 64 | 59 | 13 |
| Payables | – | 69 | 44 | 39 | 53 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | -658 | 14 | -24 | -11 | 8 |
| Cash from investing | 523 | -1 | 28 | 5 | -1 |
| Cash from financing | -10 | -16 | -6 | 5 | -6 |
| Capex | 0 | 1 | 0 | 5 | 0 |
| Free cash flow | -658 | 13 | -24 | -15 | 8 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | -831.9% | 832.2% | 89.6% | 83.3% |
| ROCE % | – | -70.5% | -11.7% | -3.5% | -91.6% |
| Debtor days | – | 150 | 203 | 233 | 236 |
| Inventory days | – | 107 | 327 | 358 | 63 |
| Payable days | – | 93 | 225 | 240 | 264 |
| Cash conversion cycle (days) | – | 164 | 305 | 351 | 35 |
| Working capital days | – | -180 | -166 | -253 | -1,461 |
Shareholding
| Holder | % (2026-03-31) |
|---|---|
| Promoters | 7.57% |
| FIIs | 1.64% |
| DIIs | 0.00% |
| of which Mutual funds | 0.00% |
| of which Insurance | 0.00% |
| Government | 0.12% |
| Public (non-institutions) | 90.67% |
| Quarter | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 20.94% | 20.94% | 20.94% | 20.94% | 7.77% | 7.77% | 7.77% | 7.57% |
| Promoter group | % |
|---|---|
| Varalwar Sandeep | 2.81% |
| Subhash Varalwar | 1.63% |
| Sheetal Varalwar | 0.83% |
| Manohar RAO Varalwar | 0.52% |
| BBR Projects Private Limited | 0.52% |
| S Raghunandan | 0.38% |
| Madhavi Varalwar | 0.24% |
| Vijaykumar Varalwar | 0.18% |
| Mamatha Gurnukar | 0.18% |
| Neelima Vijaya Varalwar | 0.12% |
| Chandrashekharrao Sudigali | 0.06% |
| Varalwar Padma | 0.04% |
| Vithabai Varalwar | 0.03% |
| Sujatha Varalwar | 0.03% |
| Santosh Varalwar | 0.00% |
| Public holders above 1% | % |
|---|---|
| Kitara Piin 1102 | 9.37% |
| William F Harvey | 1.65% |
| Sameer Mahendra Sampat | 1.64% |
| Amicorp Capital (Mauritius) Limited | 1.47% |
| Ashish Bharatkumar Shah | 1.42% |
| Monarch Networth Finserve Private Limited | 1.24% |
| Jagat Foods Private Limited | 1.12% |
47,492 shareholders. Pledged: 15.18% of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| VIVIMEDLAB | ₹50 cr | – | – | – | -91.6% | -216.2% | -27.9% | – |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2024-12-27 | Other | Annual General Meeting |
| 2023-11-07 | Other | Annual General Meeting |
| 2023-03-21 | Other | Annual General Meeting |
| 2023-02-10 | Other | Annual General Meeting |
| 2020-12-23 | Other | Annual General Meeting |
| 2019-09-23 | Other | Annual General Meeting |
| 2018-09-19 | Dividend | Annual General Meeting/Dividend Re 0.40 Per Share |
| 2017-09-21 | Dividend | Annual General Meeting/Dividend - Re 0.40 Per Share |
| 2016-09-22 | Other | Annual General Meeting |
| 2016-04-06 | Split | Face Value Split (Sub-Division) - From Rs 10/- Per Share To Rs 2/- Per Share |
| 2015-09-23 | Other | Annual General Meeting |
| 2014-09-24 | Dividend | Annual General Meeting / Dividend - Rs 3/- Per Share |
| 2013-09-24 | Dividend | Annual General Meeting / Dividend - Rs 3/- Per Share |
| 2012-09-21 | Dividend | Annual General Meeting/Dividend Rs 3 Per Share |
| 2011-09-26 | Dividend | Annual General Meeting And Dividend - Rs.2 Per Share |
| 2010-09-09 | Dividend | Annual General Meeting And Dividend Rs.1.50 Per Share |
| 2009-09-24 | Other | Agm/Div-Rs.1.50 Per Share |
| 2008-09-22 | Dividend | Agm/Dividend - 10% |
| 2007-12-20 | Other | Annual General Meeting |
| 2006-09-21 | Other | Agm |
Documents
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Annual report FY22
- Annual report FY21
- Announcements NSE filings
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | VIVIMEDLAB |
| BSE code | 532660 |
| ISIN | INE526G01021 |
| Face value | ₹2.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-23 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.